CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 46, Issue 2, 2007, Pages 242-251

  Michelson, David ^a   Read, Holly A ^b   Ruff, Dustin D ^b   Witcher, Jennifer ^b   Zhang, Shuyu ^b   McCracken, James ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Cytochrome P 450 2D6; Drug metabolism; Pharmacogenetics

Indexed keywords

ATOMOXETINE; CYTOCHROME P450 2D6; PLACEBO;

ABDOMINAL PAIN; ABRASION; ADOLESCENT; ADULT; ANOREXIA; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; BACTERIAL INFECTION; BODY WEIGHT; CARDIOVASCULAR FUNCTION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EAR INFECTION; FATIGUE; FEMALE; GASTROENTERITIS; HEART RATE; HUMAN; INFLUENZA; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE CONGESTION; PHARYNGITIS; PRIORITY JOURNAL; RASH; RHINOPHARYNGITIS; RHINORRHEA; SCHOOL CHILD; SIDE EFFECT; SINUSITIS; SOMNOLENCE; TREMOR; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOTRANSFORMATION; CHILD; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; META-ANALYSIS; POLYMORPHISM, GENETIC; PROPYLAMINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33846407239     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000246056.83791.b6     Document Type: Article

References (22)

1. Buitelaar JK, Michelson D, Danckaerts M et al. (2006), A randomized, double-blind study of continuation treatment for ADHD after one year. Biol Psychiatry Aug 4 (e-pub ahead of print)
2. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980), A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17:102-105
3. Faries DE, Yalcin I, Harder D, Heiligenstein JH (2001), Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 5:39-47
4. Guengerich FP (2005), Human cytochrome P450 enzymes. In: Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed., Ortiz de Montellano P, ed. New York: Kluwer Academic/Plenum, pp 377-530
5. Kratochvil CJ, Newcorn JH, Arnold LE et al. (2005), Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 44:915-924
6. Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK (1998), CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8:529-541
7. Michelson D, Adler L, Spencer T et al. (2003), Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112-120
8. Michelson D, Allen AJ, Busner J et al. (2002), Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901
9. Michelson D, Faries D, Wernicke J et al., Atomoxetine ADHD Study Group (2001), Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:e83
10. Physician's Desk Reference (2005), 59th ed. Montvale, NJ: Thomson Healthcare
11. Sachse C, Brockmoller J, Bauer S, Roots I (1997), Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295
12. Sauer JM, Long AJ, Ring B et al. (2004), Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther 308:410-418
13. Spencer TJ, Heiligenstein JH, Biederman J et al. (2002), Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140-1147
14. Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J (2005), Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 116:e74-e80
15. Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoqvist F (1988), Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44:431-435
16. Strattera [package insert]. Indianapolis, IN: Eli Lilly & Co; 2005
17. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S (1999), Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 65:570-575
18. Wernicke JF, Faries D, Girod D et al. (2003), Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26:729-740
19. Witcher JW, Kurtz DL, Sauer JM, Michelson D, Smith BP, Ruff DD (2002), Pharmacokinetic/pharmacodynamic relationship of atomoxetine exposure and efficacy in child and adolescent ADHD patients. Paper presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, May 18-23
20. Witcher JW, Long A, Smith B et al. (2003), Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 13:53-63
21. Wolf CR, Smith G (1999), Cytochrome P450 CYP2D6. IARC Sci Publ 148:209-229
22. Yang L, Wang YF, Li J, Faraone SV (2004), Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry 43:1154-1158